These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10762139)

  • 1. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
    Chase TN; Oh JD
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S122-9; discussion S129-30. PubMed ID: 10762139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
    Oh JD; Chase TN
    Amino Acids; 2002; 23(1-3):133-9. PubMed ID: 12373527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
    Wessell RH; Ahmed SM; Menniti FS; Dunbar GL; Chase TN; Oh JD
    Neuropharmacology; 2004 Aug; 47(2):184-94. PubMed ID: 15223297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
    Dunah AW; Wang Y; Yasuda RP; Kameyama K; Huganir RL; Wolfe BB; Standaert DG
    Mol Pharmacol; 2000 Feb; 57(2):342-52. PubMed ID: 10648644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
    Mouradian MM; Chase TN
    Exp Neurol; 1997 Mar; 144(1):51-7. PubMed ID: 9126152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms.
    Chase TN; Oh JD; Konitsiotis S
    J Neurol; 2000 Apr; 247 Suppl 2():II36-42. PubMed ID: 10991664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal plasticity and extrapyramidal motor dysfunction.
    Chase TN
    Parkinsonism Relat Disord; 2004 Jul; 10(5):305-13. PubMed ID: 15196510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?
    Calabresi P; Giacomini P; Centonze D; Bernardi G
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S60-8; discussion S68-9. PubMed ID: 10762133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
    Marin C; Jimenez A; Bonastre M; Chase TN; Tolosa E
    Synapse; 2000 Jun; 36(4):267-74. PubMed ID: 10819904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
    Hallett PJ; Dunah AW; Ravenscroft P; Zhou S; Bezard E; Crossman AR; Brotchie JM; Standaert DG
    Neuropharmacology; 2005 Mar; 48(4):503-16. PubMed ID: 15755478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motor response complications and the function of striatal efferent systems.
    Chase TN; Mouradian MM; Engber TM
    Neurology; 1993 Dec; 43(12 Suppl 6):S23-7. PubMed ID: 8264907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.
    Oh JD; Vaughan CL; Chase TN
    Brain Res; 1999 Mar; 821(2):433-42. PubMed ID: 10064831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
    Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease.
    Betarbet R; Poisik O; Sherer TB; Greenamyre JT
    Exp Neurol; 2004 May; 187(1):76-85. PubMed ID: 15081590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neostriatal mechanisms in Parkinson's disease.
    Chase TN; Oh JD; Blanchet PJ
    Neurology; 1998 Aug; 51(2 Suppl 2):S30-5. PubMed ID: 9711978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine-mediated gene regulation in models of Parkinson's disease.
    Gerfen CR
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S42-50; discussion S50-2. PubMed ID: 10762131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
    Steece-Collier K; Chambers LK; Jaw-Tsai SS; Menniti FS; Greenamyre JT
    Exp Neurol; 2000 May; 163(1):239-43. PubMed ID: 10785463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.